Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics, today announced that the FDA issued IND Number 27375 to the Company in connection with its Clinical Trial application to use ImmCelz^® to treat stroke victims.

The ImmCelz^® treatment involves utilization of stem cells outside of the body to "reprogram" the patient's own immune cells so as to endow the immune cells with regenerative properties.  In contrast to other stem cell based approaches, the immune cells are significantly smaller in size than stem cells and are believed to more effectively penetrate areas of the damaged tissue and induce regeneration.

"This is a major milestone for the Company," exclaimed Timothy Warbington, President and CEO of the Company. "We look forward to hearing back from the FDA and moving ImmCelz^® rapidly to the clinic."

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in regenerative medicine-stem cell technology in the fields of immunotherapy, urology, neurology and orthopedics, and is listed on the OTC under the ticker symbol CELZ. For further information about the company, please visit www.creativemedicaltechnology.com. 

Forward Looking Statements

OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.